GLP1-RA did not reduce the MACE risk in patients with severe kidney disease (baseline eGFR < 60mL/min/1.73m2) but reduce the risk of MACE in moderate kidney disease (baseline eGFR ≥ 60mL/min/1.73m2) (Figure S1 shows this in more detail [see Additional file 1]). The gene discussed is GLP1R; the disease is kidney disorder.